Analysts Set COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) Price Target at $17.00

Key Points

• COMPASS Pathways PLC has received a consensus rating of "Moderate Buy" from seven analysts, with one hold and six buy ratings, and an average twelve-month target price of $17.00.
• The company's latest earnings report showed an earnings per share of (-$0.38), slightly missing analysts' expectations and forecasting a -2.33 EPS for the current year.
• COMPASS Pathways is developing COMP360, a psilocybin therapy currently in Phase III clinical trials for treatment-resistant depression.

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $16.2857.

Several research firms have recently issued reports on CMPS. Evercore ISI reaffirmed an "in-line" rating and issued a $6.00 price objective (down previously from $11.00) on shares of COMPASS Pathways in a research note on Monday, June 23rd. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $15.00 price objective on shares of COMPASS Pathways in a research note on Friday, August 1st. HC Wainwright lowered their price objective on COMPASS Pathways from $45.00 to $40.00 and set a "buy" rating for the company in a research note on Monday. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $12.00 price objective on shares of COMPASS Pathways in a research note on Tuesday, May 27th.

Institutional Trading of COMPASS Pathways

Several hedge funds have recently bought and sold shares of CMPS. RTW Investments LP acquired a new stake in COMPASS Pathways in the 4th quarter valued at $11,714,000. Nantahala Capital Management LLC grew its position in COMPASS Pathways by 182.9% in the 1st quarter. Nantahala Capital Management LLC now owns 2,829,232 shares of the company's stock valued at $8,092,000 after purchasing an additional 1,829,232 shares during the period. Vivo Capital LLC grew its position in COMPASS Pathways by 109.1% in the 1st quarter. Vivo Capital LLC now owns 3,362,385 shares of the company's stock valued at $9,616,000 after purchasing an additional 1,754,385 shares during the period. Altium Capital Management LLC bought a new position in COMPASS Pathways during the 4th quarter valued at $5,384,000. Finally, Woodline Partners LP lifted its stake in COMPASS Pathways by 279.9% during the 1st quarter. Woodline Partners LP now owns 1,754,856 shares of the company's stock valued at $5,019,000 after acquiring an additional 1,292,927 shares in the last quarter. Institutional investors and hedge funds own 46.19% of the company's stock.

COMPASS Pathways Price Performance

Shares of CMPS stock traded down $0.11 on Friday, reaching $4.38. The company had a trading volume of 581,582 shares, compared to its average volume of 1,833,271. The stock has a market capitalization of $419.74 million, a PE ratio of -2.38 and a beta of 2.17. The company has a quick ratio of 8.82, a current ratio of 8.82 and a debt-to-equity ratio of 0.16. COMPASS Pathways has a one year low of $2.25 and a one year high of $8.54. The business's 50-day moving average is $4.00 and its 200 day moving average is $3.82.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last posted its earnings results on Thursday, July 31st. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.01). Equities research analysts forecast that COMPASS Pathways will post -2.33 EPS for the current fiscal year.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.